Premium
Treatment of acute myelogenous leukemia in patients over 50 years of age with V‐TAD: A southwest oncology group study
Author(s) -
Bigelow Carolyn L.,
Kopecky Kenneth,
Files Joe C.,
Head David,
Lipschitz David A.,
Grever Michael,
Appelbaum Frederick R.
Publication year - 1995
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830480404
Subject(s) - medicine , leukemia , oncology , hematology
Abstract Acute myelogenous leukemia (AML) in the elderly continues to have a poor prognosis and new treatment approaches are needed. This Phase II trial was undertaken to evaluate the complete remission rate and toxicity of a chemotherapeutic regimen including etoposide and 6‐thioguanine, combined with reduced doses of cytosine arabinoside and daunorubicin (V‐TAD) in individuals greater than 50 years of age with AML. Thirty‐five patients, ranging in age from 51 to 80 years (median, 66 years), were registered onto the study. Twenty‐nine patients were entered at the first dose level (daunomycin 20 mg/m 2 days 1 and 2, ara‐C 75 mg/m 2 days 1‐5, 6‐thioguanine 75 mg/m 2 every 12 hr days 1‐5, and etoposide 50 mg/m 2 days 1, 2, and 3) and six patients underwent therapy at the second dose level (ara‐C 75 mg/m 2 days 1‐7 with the remainder of the regimen unchanged). After achieving a complete remission, patients underwent two to three consolidation cycles of chemotherapy. Thirty‐one patients were evaluable for response. Thirteen patients (ten of twenty‐five at the first dose level and three of six at the second dose level) achieved a complete remission (42%). Median remission duration was 6 months (range 1‐21 months). The current regimen, while tolerated, did not result in improved survival compared with prior treatment regimens because of a high incidence of resistant and recurrent leukemia. © 1995 Wiley‐Liss, Inc.